Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks UK Distribution Deal With YouMed

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag has signed a distribution and commercialization deal with YouMed for its PCR-based Amplidiag platform.

Under the terms of the agreement, YouMed will sell and market Amplidiag and its associated menu of in vitro diagnostic tests for gastrointestinal infections, including bacterial, viral, and parasitic infections. The distribution agreement also includes the upcoming, automated Amplidiag Easy system.

Financial and other terms of the agreement were not disclosed.

"There is an unmet need in the UK molecular diagnostic market for accurate, reliable testing for gastrointestinal pathogens. We are confident the Mobidiag assays and systems can have a positive impact on management of patients suffering from these infections," YouMed Managing Director Christopher Brain said in a statement.

Mobidiag CEO Tuomas Tenkanen added that expanding its distribution network to include the UK was an important step for the company. Since the beginning of September, the company has also announced new distribution deals for Sweden and Norway, Central and Eastern Europe, and Portugal

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.